BOSSI, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 461
EU - Europa 303
AS - Asia 169
SA - Sud America 25
Continente sconosciuto - Info sul continente non disponibili 3
Totale 961
Nazione #
US - Stati Uniti d'America 457
IT - Italia 99
SG - Singapore 82
RU - Federazione Russa 63
DE - Germania 46
IE - Irlanda 42
CN - Cina 25
HK - Hong Kong 25
BR - Brasile 21
SE - Svezia 21
ID - Indonesia 17
TR - Turchia 8
IN - India 7
GB - Regno Unito 6
AT - Austria 5
CA - Canada 4
FI - Finlandia 4
UA - Ucraina 4
EU - Europa 3
FR - Francia 3
LT - Lituania 3
AR - Argentina 2
CH - Svizzera 2
DK - Danimarca 2
NL - Olanda 2
PH - Filippine 2
AZ - Azerbaigian 1
CO - Colombia 1
PE - Perù 1
PT - Portogallo 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 961
Città #
Ann Arbor 211
Singapore 51
Dublin 42
Milan 32
Frankfurt am Main 28
Wilmington 27
Hong Kong 25
Chandler 23
New York 22
Santa Clara 20
Jakarta 17
Fairfield 12
Ashburn 11
Shanghai 11
Seattle 9
Cambridge 8
Woodbridge 8
Houston 7
Princeton 6
Fremont 5
Kocaeli 5
Los Angeles 5
Duncan 4
Helsinki 4
Nuremberg 4
Rome 4
Turin 4
Ankara 3
Bologna 3
Colorado Springs 3
Lawrence 3
Romola 3
Abbiategrasso 2
Aurora 2
Beijing 2
Bonndorf 2
Brugherio 2
Carugate 2
Desio 2
Düsseldorf 2
Fisciano 2
Guangzhou 2
Hebei 2
Lissone 2
Manila 2
Monmouth Junction 2
Monza 2
Moscow 2
Nanjing 2
Novo Hamburgo 2
Ottawa 2
São Paulo 2
Toronto 2
Vicenza 2
Vienna 2
Altamura 1
Amparo 1
Andover 1
Austin 1
Baku 1
Bari 1
Boardman 1
Bogotá 1
Brasília 1
Canobbio 1
Carate Brianza 1
Chicago 1
Corsico 1
Curitiba 1
Falls Church 1
Grafing 1
Guarulhos 1
Guernica 1
Ho Chi Minh City 1
Hounslow 1
Hyderabad 1
Ibotirama 1
Ivrea 1
Jacksonville 1
Jinan 1
Kaunas 1
Lauterbourg 1
Leawood 1
Leopoldina 1
London 1
Mogi das Cruzes 1
Moreno 1
Morretes 1
Mountain View 1
Munich 1
Nanchang 1
Navoiy 1
Newark 1
Niterói 1
Paracatu 1
Portsmouth 1
Poá 1
Poços de Caldas 1
Pune 1
Redmond 1
Totale 711
Nome #
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 276
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 206
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 162
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 87
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 84
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 76
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 71
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 40
Totale 1.002
Categoria #
all - tutte 4.146
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.146


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202036 0 0 0 0 0 0 0 0 0 21 9 6
2020/2021263 9 2 22 35 26 37 28 25 19 18 25 17
2021/202262 14 14 11 3 1 5 2 2 1 1 3 5
2022/2023101 6 27 10 3 11 12 4 2 5 1 10 10
2023/2024186 5 8 20 9 30 45 30 2 19 2 2 14
2024/2025313 10 33 25 21 33 29 38 9 42 73 0 0
Totale 1.002